Abstract
Although the development of novel drugs and combination regimens for tuberculosis has accelerated in recent years, the pipeline remains thin and major challenges remain to be addressed in efficiently evaluating newer drugs to improve treatment outcomes, shorten duration of therapy and tackle drug resistance.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Combining host-derived biomarkers with patient characteristics improves signature performance in predicting tuberculosis treatment outcomes
Communications Biology Open Access 09 July 2020
-
ArCH(OMe)2 - a PtIV-catalyst originator for diverse annulation catalysis
Scientific Reports Open Access 18 October 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
World Health Organization. Global tuberculosis control 2011. WHO website [online], (WHO, Geneva, Switzerland, 2011).
World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO website [online], (WHO, Geneva, Switzerland, 2012).
Orenstein, E. W. et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis. 9, 153–161 (2009).
STOP TB Partnership. Working group on new TB drugs discovery portfolio. New TB Drugs website [online], (2011).
Phillips, P. et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J. Infect. Dis. (in the press).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Zumla, A., Hafner, R., Lienhardt, C. et al. Advancing the development of tuberculosis therapy. Nat Rev Drug Discov 11, 171–172 (2012). https://doi.org/10.1038/nrd3694
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3694
This article is cited by
-
Combining host-derived biomarkers with patient characteristics improves signature performance in predicting tuberculosis treatment outcomes
Communications Biology (2020)
-
ArCH(OMe)2 - a PtIV-catalyst originator for diverse annulation catalysis
Scientific Reports (2013)